These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

274 related items for PubMed ID: 27470708

  • 1. Microparticle content of platelet concentrates is predicted by donor microparticles and is altered by production methods and stress.
    Maurer-Spurej E, Larsen R, Labrie A, Heaton A, Chipperfield K.
    Transfus Apher Sci; 2016 Aug; 55(1):35-43. PubMed ID: 27470708
    [Abstract] [Full Text] [Related]

  • 2. Microparticle detection to guide platelet management for the reduction of platelet refractoriness in children - A study proposal.
    Kanzler P, Mahoney A, Leitner G, Witt V, Maurer-Spurej E.
    Transfus Apher Sci; 2017 Feb; 56(1):39-44. PubMed ID: 28089410
    [Abstract] [Full Text] [Related]

  • 3. Effect of Mirasol pathogen reduction technology system on in vitro quality of MCS+ apheresis platelets.
    Mastroianni MA, Llohn AH, Akkök ÇA, Skogheim R, Ødegaard ER, Nybruket MJ, Flesland A, Mousavi SA.
    Transfus Apher Sci; 2013 Oct; 49(2):285-90. PubMed ID: 23820429
    [Abstract] [Full Text] [Related]

  • 4. Microparticle and mitochondrial release during extended storage of different types of platelet concentrates.
    Marcoux G, Duchez AC, Rousseau M, Lévesque T, Boudreau LH, Thibault L, Boilard E.
    Platelets; 2017 May; 28(3):272-280. PubMed ID: 27681879
    [Abstract] [Full Text] [Related]

  • 5. Pooled platelet concentrates: an alternative to single donor apheresis platelets?
    Pietersz RN.
    Transfus Apher Sci; 2009 Oct; 41(2):115-9. PubMed ID: 19716340
    [Abstract] [Full Text] [Related]

  • 6. Comparison of the platelet activation status of single-donor platelets obtained with two different cell separator technologies.
    Millar D, Hayes C, Jones J, Klapper E, Kniep JN, Luu HS, Noland DK, Petitti L, Poisson JL, Spaepen E, Ye Z, Maurer-Spurej E.
    Transfusion; 2020 Sep; 60(9):2067-2078. PubMed ID: 32729161
    [Abstract] [Full Text] [Related]

  • 7. Platelet-derived extracellular vesicles in plateletpheresis concentrates as a quality control approach.
    Black A, Pienimaeki-Roemer A, Kenyon O, Orsó E, Schmitz G.
    Transfusion; 2015 Sep; 55(9):2184-96. PubMed ID: 26032769
    [Abstract] [Full Text] [Related]

  • 8. Apheresis platelet concentrates contain platelet-derived and endothelial cell-derived microparticles.
    Rank A, Nieuwland R, Liebhardt S, Iberer M, Grützner S, Toth B, Pihusch R.
    Vox Sang; 2011 Feb; 100(2):179-86. PubMed ID: 20701731
    [Abstract] [Full Text] [Related]

  • 9. Functional characteristics and clinical effectiveness of platelet concentrates treated with riboflavin and ultraviolet light in plasma and in platelet additive solution.
    Ignatova AA, Karpova OV, Trakhtman PE, Rumiantsev SA, Panteleev MA.
    Vox Sang; 2016 Apr; 110(3):244-52. PubMed ID: 26646605
    [Abstract] [Full Text] [Related]

  • 10. Buffy-coat-derived pooled platelet concentrates and apheresis platelet concentrates: which product type should be preferred?
    Schrezenmeier H, Seifried E.
    Vox Sang; 2010 Jul 01; 99(1):1-15. PubMed ID: 20059760
    [Abstract] [Full Text] [Related]

  • 11. In-vivo evaluation of random donor platelet concentrates from pooled buffy coats.
    Klüter H, Dörges L, Maass E, Wagner T, Bartels H, Kirchner H.
    Ann Hematol; 1996 Aug 01; 73(2):85-9. PubMed ID: 8774617
    [Abstract] [Full Text] [Related]

  • 12. Implications of a switch to a 100% apheresis platelet supply for patients and for blood donors: a risk benefit analysis.
    Thiele T, Alt-Mayer T, Greinacher A, Bux J.
    Vox Sang; 2016 Nov 01; 111(4):350-356. PubMed ID: 27432635
    [Abstract] [Full Text] [Related]

  • 13. Differences in levels of platelet-derived microparticles in platelet components prepared using the platelet rich plasma, buffy coat, and apheresis procedures.
    Noulsri E, Udomwinijsilp P, Lerdwana S, Chongkolwatana V, Permpikul P.
    Transfus Apher Sci; 2017 Apr 01; 56(2):135-140. PubMed ID: 28029568
    [Abstract] [Full Text] [Related]

  • 14. Platelet derived cytokine accumulation in platelet concentrates treated for pathogen reduction.
    Tauszig ME, Picker SM, Gathof BS.
    Transfus Apher Sci; 2012 Feb 01; 46(1):33-7. PubMed ID: 22119364
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Early storage lesions in apheresis platelets are induced by the activation of the integrin αIIbβ₃ and focal adhesion signaling pathways.
    Thiele T, Iuga C, Janetzky S, Schwertz H, Gesell Salazar M, Fürll B, Völker U, Greinacher A, Steil L.
    J Proteomics; 2012 Dec 05; 76 Spec No.():297-315. PubMed ID: 22634086
    [Abstract] [Full Text] [Related]

  • 17. [Platelet concentrates from whole-blood donations (buffy-coat) or apheresis: which one to use?].
    Lozano ML, Rivera J, Vicente V.
    Med Clin (Barc); 2012 May 05; 138(12):528-33. PubMed ID: 21807386
    [Abstract] [Full Text] [Related]

  • 18. High platelet content can increase storage lesion rates following Intercept pathogen inactivation primarily in platelet concentrates prepared by apheresis.
    Feys HB, Devloo R, Sabot B, De Pourcq K, Coene J, Compernolle V.
    Vox Sang; 2017 Nov 05; 112(8):751-758. PubMed ID: 28960339
    [Abstract] [Full Text] [Related]

  • 19. Bacterial survival and distribution during buffy coat platelet production.
    Taha M, Kalab M, Yi QL, Maurer E, Jenkins C, Schubert P, Ramirez-Arcos S.
    Vox Sang; 2016 Nov 05; 111(4):333-340. PubMed ID: 27432557
    [Abstract] [Full Text] [Related]

  • 20. Proteomics of apheresis platelet supernatants during routine storage: Gender-related differences.
    Dzieciatkowska M, D'Alessandro A, Burke TA, Kelher MR, Moore EE, Banerjee A, Silliman CC, West BF, Hansen KC.
    J Proteomics; 2015 Jan 01; 112():190-209. PubMed ID: 25201077
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.